Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
Protea Biosciences Group, Inc. and InSphero AG jointly announced that they have entered into a collaboration that will combine each company's respective 3D technology. InSphero AG is the leading supplier of 3D organotypic microtissues for in vitro toxicology and efficacy studies, with models derived from liver, pancreas, tumor, and brain tissue that yield a high level of predictability during drug development compared to traditional 2-dimensional cell culture and other in vitro model systems.
View full press release